Oritavancin: First Global Approval

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

(2014) G. Ralph Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oritavancin: Mechanism of Action

(2012) George G. Zhanel et al.   CLINICAL INFECTIOUS DISEASES

Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States

(2012) Rodrigo E. Mendes et al.   CLINICAL INFECTIOUS DISEASES

Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial

(2011) Lala M. Dunbar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Lipoglycopeptides

(2010) George G. Zhanel et al.   DRUGS

Oritavancin, a New Lipoglycopeptide Antibiotic: Results From a Thorough QT Study

(2010) Borje Darpo et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

(2009) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

(2009) G. A. McKay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY